Seventh Sense Biosystems' proprietary technology platform is being developed by the experienced Seventh Sense scientific team to eliminate the discomfort, inconvenience and expert intervention associated with traditional blood sampling. The company's broad On Vivo™ technology encompasses proprietary blood collection, assay chemistries and data handling, and can be leveraged across the diagnostic spectrum, from point-of-care and central lab analytical systems to fully integrated on-skin diagnostics.
The Touch Activated Phlebotomy™ (TAP) device is the first product developed using Seventh Sense's proprietary technology platform and was recently recognized with an Edison Award™ and received a Grand Challenges in Global Health grant from the Bill & Melinda Gates Foundation.